Renalis Appoints New Board Member and Announces New CTO
The company announced Barbara (Be) Stark to the Board and Fares Bouchedid as Chief Technology Officer.
CLEVELAND, March 22, 2002 - Renalis, the first company focused exclusively on developing prescribed digital therapeutics for pelvic health disorders, today announced the addition of Barbara (Be) Stark to its Board of Directors and named Fares Bouchedid as its new Chief Technology Officer.
“It is a privilege to welcome these two esteemed individuals to the Renalis Team. Each brings decades of experience and a background that is uniquely positioned to drive the growth of our organization,” said Missy Lavender, CEO & Founder of Renalis. “Especially as we look forward to our pathway of being the leader in the space of prescribed digital therapeutics for pelvic health disorders, Be and Fares will be pivotal in securing Renalis as a leader in this industry.”
Be Stark has over 30 years of experience driving strategic growth for healthcare service organizations focused on providing value-based solutions to payors and risk-based providers. An accomplished and strategic sales leader, Ms. Stark has held senior-level sales leadership roles in early, mid and late-stage companies across healthcare verticals including risk-based home healthcare, medical devices, disease management, and bio-pharmaceuticals. She is currently Senior Vice President and Head of Managed Markets for digital therapeutics company, DarioHealth.
Fares Bouchedid has over 15 years in technology leadership positions with a track record of scaling and improving organization-wide technologies and processes. He specializes in cloud infrastructure, microservices, and serverless architectures. Fares leads by example and is fond of training and mentoring others on security, best practices, and conventions. He is a certified Agile Scrum Professional with demonstrated capability for transitioning organizations from waterfall to agile methodology. Fares has a Bachelor of Science, Master in Computer Science, and Master in Business Administration from Youngstown State University.
About Renalis: Renalis is developing FDA-cleared prescription digital therapeutics for pelvic health disorders to improve the effectiveness and efficiency of patient/provider interaction, optimize patient outcomes, and decrease healthcare costs. Renalis’ first two commercial products are digital therapeutics for chronic bladder conditions in women.
Contact: Missy Lavender, Founder, CEO
Email: missy@renalis.health
Phone: (312) 287-1951
